Drugs / HPP737
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04714294 | Sep 2020 → May 2021 | — | Newsoara Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07707141 | Mar → Dec 2021 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07712731 | Apr 2025 → Apr 2026 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07712705 | Apr → Sep 2023 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06584058 | Aug 2024 → Jul 2025 overdue | psoriasis | Newsoara Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-09-23 | vTv Therapeutics | Results vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis vtvtherapeutics.com ↗
Dose escalation up to 20mg/day demonstrated approximate dose proportional increases in exposure, while maintaining a favorable safety and tolerability profile with no dose limiting safety or tolerability findings observed. |
| 2021-06-29 | vTv Therapeutics | Results vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 vtvtherapeutics.com ↗
In the phase 1 single ascending dose study presented here and a subsequent multiple-ascending dose study, HPP737 was well tolerated, with little or no gastrointestinal adverse events, such as nausea, vomiting or diarrhea, across the range of doses tested. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPP737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07707141 ↗ |
| Action | Inhibit | “HPP737 as an oral PDE4 inhibitor” NCT04714294 ↗ |
| Route | Oral | “taken orally (by mouth)” NCT04714294 ↗ |
| Target | PDE4B | “HPP737 is designed to preferentially inhibit PDE4B” NCT07712731 ↗ |